Thompson Davis & CO. Inc. Takes $545,000 Position in Kenvue Inc. $KVUE

Thompson Davis & CO. Inc. purchased a new position in shares of Kenvue Inc. (NYSE:KVUE) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 26,040 shares of the company’s stock, valued at approximately $545,000.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Trust Co. of Vermont raised its holdings in Kenvue by 266.8% during the second quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock worth $33,000 after buying an additional 1,150 shares during the last quarter. Truvestments Capital LLC bought a new stake in shares of Kenvue during the first quarter worth about $37,000. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock worth $39,000 after acquiring an additional 1,287 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich boosted its stake in Kenvue by 120.6% during the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company’s stock valued at $41,000 after purchasing an additional 929 shares during the last quarter. Finally, First Pacific Financial acquired a new position in Kenvue during the 2nd quarter valued at about $54,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

NYSE:KVUE opened at $16.96 on Thursday. The company has a market capitalization of $32.50 billion, a P/E ratio of 22.47, a P/E/G ratio of 2.44 and a beta of 0.71. The business has a fifty day simple moving average of $16.53 and a two-hundred day simple moving average of $20.15. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm’s quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be given a $0.2075 dividend. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 annualized dividend and a dividend yield of 4.9%. Kenvue’s payout ratio is 110.67%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Evercore ISI set a $18.00 target price on Kenvue in a report on Tuesday, October 28th. JPMorgan Chase & Co. cut their price objective on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Edward Jones lowered shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. The Goldman Sachs Group dropped their price target on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a research report on Thursday, October 2nd. Finally, Rothschild Redb upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a report on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $20.23.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.